Humulin M3

Humulin M3 is a prescription injectable solution that contains recombinant human insulin at a concentration of 100 U/mL, formulated as a premixed suspension of 30 % regular insulin and 70 % NPH insulin. It is supplied for subcutaneous administration and is used in the European market to help manage blood glucose in patients with diabetes. Humulin M3 is indicated for type 1 and type 2 diabetes and provides basal and insulin coverage in one injection.

Humulin M3 is prescribed to improve glycemic control in adults and children with diabetes.

- As basal insulin in combination with meals for type 1 diabetes. - To cover mealtime (prandial) glucose spikes in type 2 diabetes when diet and oral agents are insufficient. - For patients who prefer a twice‑daily injection schedule. - In insulin‑treated patients requiring a predictable mix of short‑acting and intermediate‑acting insulin. - May be used during pregnancy under medical supervision (category B).

Like other insulin preparations, Humulin M3 may cause adverse reactions that vary in frequency and severity.

Common: - Hypoglycemia (low blood glucose), which may present as shakiness, sweating, confusion, or dizziness. - Injection‑site reactions such as mild redness, swelling, itching or bruising. - Lipodystrophy, including localized fat accumulation (lipohypertrophy) or loss (lipoatrophy) at the site of repeated injections. - Gradual weight gain that can accompany improved glycemic control and increased caloric storage.

Serious: - Severe hypoglycemia resulting in loss of consciousness, seizures, or the need for external glucose administration. - Allergic responses ranging from urticaria and angioedema to rare anaphylactic shock. - Persistent hyperglycemia or ketoacidosis suggesting inadequate insulin effect or resistance. - Fluid retention, peripheral edema, or worsening heart failure in patients with cardiac disease.

Healthcare providers should consider several precautions before prescribing Humulin M3 to ensure safe and effective use.

- Assess renal and hepatic function, as impairment may alter insulin clearance. - Review patient’s history of hypoglycemia unawareness or recurrent episodes. - Adjust doses during periods of illness, surgery, or changes in physical activity. - Monitor blood glucose closely during pregnancy; insulin requirements often change. - Avoid use in patients with known hypersensitivity to recombinant human insulin or any excipients. - Caution in the elderly, who may have variable absorption and increased risk of hypoglycemia. - Educate patients on proper injection technique and rotation of sites.

Humulin M3 can interact with other medicines, affecting glucose control or insulin action.

Avoid: - Concurrent use of high‑dose sulfonylureas or meglitinides, which may precipitate severe hypoglycemia. - Beta‑blockers that mask hypoglycemia symptoms and may blunt recovery.

Use with caution: - Corticosteroids, thiazide diuretics, and growth hormone, which can raise blood glucose and require dose adjustments. - ACE inhibitors and ARBs, which may enhance insulin sensitivity and increase hypoglycemia risk. - Oral contraceptives or hormone replacement therapy, potentially altering insulin requirements. - Alcohol consumption, especially in excess, which can cause unpredictable glucose fluctuations.